Your session is about to expire
← Back to Search
Chemotherapy + Immunotherapy for Lung Cancer
Study Summary
This trial is testing a new way to treat lung or head and neck cancer by combining chemotherapy and immunotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is not small cell carcinoma.My brain scans show no worsening after treatment for brain metastases.I haven't taken steroids for at least 7 days.I am taking medication to control seizures.I have another cancer type, but it won't affect this trial's treatment.My cancer does not have treatable mutations like EGFR (except exon 20), BRAF (V600), MET Exon14, ALK, or ROS1.I have a history of cancer.I haven't had any cancer except for skin cancer in the last 5 years.I have had a condition where my lymphocytes grow abnormally.My lung cancer is either squamous cell carcinoma or a nonsquamous type like adenocarcinoma.My lung cancer is at stage IV.My cancer is a mix of squamous and another type, and I will be treated in Study Arm 1.I can take care of myself and am up and about more than half of my waking hours.I am 18 years old or older.My cancer can be measured by tests or I have cancerous fluid in my chest.
- Group 1: Squamous Lung Cancer
- Group 2: Non-Squamous Lung Cancer
- Group 3: Head and Neck Squamous Cell Carcinoma
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there various locations where this research is being conducted around the state?
"Patients can enroll in this clinical trial at 11 different locations, including RWJBarnabas Health - Saint Barnabas Medical Center in Livingston, Robert Wood Johnson Somerset Hospital in Somerville and RWJBarnabas Health - Community Medical Center in Toms River."
How many participants are engaged in this clinical trial?
"Affirmative. The clinicaltrials.gov database reveals that this research undertaking, initially posted on April 28th 2022, is currently accepting participants. 150 people are required to join from 11 different medical facilities."
What potential harms could be associated with the administration of Pembrolizumab?
"Our internal rating at Power granted pembrolizumab a 2, taking into consideration the Phase II trial's data on safety but absence of information concerning efficacy."
Are there any opportunities to enroll in this clinical study at present?
"Yes, this medical trial is still open for applicants. It was first posted on April 28th 2022 and the criteria were revised as recently as October 13th of that same year."
Share this study with friends
Copy Link
Messenger